Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 7 | 2020 | 358 | 1.210 |
Why?
|
| Continuity of Patient Care | 4 | 2017 | 174 | 0.700 |
Why?
|
| Patient Participation | 3 | 2020 | 230 | 0.650 |
Why?
|
| Primary Health Care | 4 | 2024 | 690 | 0.610 |
Why?
|
| Patient Readmission | 3 | 2015 | 430 | 0.500 |
Why?
|
| Office Visits | 2 | 2014 | 48 | 0.460 |
Why?
|
| Patient Discharge | 6 | 2017 | 511 | 0.440 |
Why?
|
| Reminder Systems | 3 | 2020 | 74 | 0.430 |
Why?
|
| Ambulatory Care | 2 | 2014 | 311 | 0.410 |
Why?
|
| Text Messaging | 3 | 2020 | 85 | 0.340 |
Why?
|
| Patient Care | 2 | 2020 | 80 | 0.300 |
Why?
|
| Patient Portals | 2 | 2020 | 49 | 0.300 |
Why?
|
| Health Information Interoperability | 2 | 2018 | 4 | 0.290 |
Why?
|
| Vaccination | 2 | 2020 | 363 | 0.260 |
Why?
|
| Aged | 20 | 2024 | 14394 | 0.240 |
Why?
|
| Smoking Cessation | 2 | 2022 | 550 | 0.240 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2013 | 144 | 0.230 |
Why?
|
| Medication Errors | 3 | 2021 | 109 | 0.230 |
Why?
|
| Aged, 80 and over | 12 | 2022 | 5447 | 0.230 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2023 | 23 | 0.200 |
Why?
|
| Mobile Applications | 2 | 2024 | 136 | 0.190 |
Why?
|
| Hypertension | 2 | 2020 | 584 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 735 | 0.180 |
Why?
|
| Drug Monitoring | 3 | 2011 | 121 | 0.180 |
Why?
|
| Medication Systems | 1 | 2021 | 17 | 0.180 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 419 | 0.180 |
Why?
|
| Influenza, Human | 2 | 2020 | 208 | 0.170 |
Why?
|
| Male | 19 | 2024 | 29821 | 0.170 |
Why?
|
| Humans | 28 | 2024 | 63297 | 0.170 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 65 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 143 | 0.160 |
Why?
|
| Communication | 1 | 2024 | 571 | 0.160 |
Why?
|
| Female | 19 | 2024 | 32791 | 0.160 |
Why?
|
| Pharmacists | 1 | 2021 | 126 | 0.160 |
Why?
|
| Physicians, Primary Care | 2 | 2017 | 78 | 0.160 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 416 | 0.150 |
Why?
|
| Health Planning Guidelines | 1 | 2018 | 32 | 0.140 |
Why?
|
| Population Health | 1 | 2018 | 17 | 0.140 |
Why?
|
| Patient Selection | 1 | 2020 | 488 | 0.140 |
Why?
|
| Motivation | 1 | 2020 | 285 | 0.140 |
Why?
|
| Accidental Falls | 1 | 2018 | 127 | 0.130 |
Why?
|
| Influenza Vaccines | 1 | 2018 | 99 | 0.130 |
Why?
|
| Massachusetts | 3 | 2021 | 2075 | 0.130 |
Why?
|
| Consensus | 1 | 2018 | 228 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2014 | 695 | 0.130 |
Why?
|
| Social Determinants of Health | 1 | 2018 | 130 | 0.120 |
Why?
|
| Transitional Care | 1 | 2015 | 25 | 0.120 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 247 | 0.120 |
Why?
|
| Middle Aged | 10 | 2024 | 17553 | 0.120 |
Why?
|
| Medical Informatics | 1 | 2015 | 73 | 0.120 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 83 | 0.120 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 12 | 0.110 |
Why?
|
| Meaningful Use | 1 | 2013 | 8 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 1199 | 0.100 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2013 | 62 | 0.100 |
Why?
|
| Health Records, Personal | 1 | 2013 | 26 | 0.100 |
Why?
|
| Metformin | 1 | 2014 | 73 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2013 | 106 | 0.100 |
Why?
|
| Physicians | 1 | 2018 | 471 | 0.100 |
Why?
|
| Comorbidity | 3 | 2023 | 1121 | 0.090 |
Why?
|
| Ambulatory Care Information Systems | 1 | 2012 | 7 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 2 | 2010 | 105 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 219 | 0.090 |
Why?
|
| Pharmaceutical Preparations | 2 | 2010 | 123 | 0.090 |
Why?
|
| Weight Loss | 1 | 2013 | 272 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 337 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 158 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 255 | 0.080 |
Why?
|
| Safety Management | 1 | 2010 | 137 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2460 | 0.070 |
Why?
|
| Telemedicine | 1 | 2013 | 323 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2014 | 6631 | 0.070 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 2 | 2004 | 47 | 0.070 |
Why?
|
| Hospitalization | 3 | 2021 | 1357 | 0.070 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 166 | 0.060 |
Why?
|
| Adult | 5 | 2024 | 16784 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2024 | 263 | 0.050 |
Why?
|
| Time Factors | 3 | 2017 | 3762 | 0.050 |
Why?
|
| Incidence | 3 | 2014 | 1375 | 0.050 |
Why?
|
| Group Practice | 1 | 2003 | 12 | 0.050 |
Why?
|
| Drug Therapy | 1 | 2003 | 56 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1543 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 76 | 0.050 |
Why?
|
| Carbon Monoxide | 1 | 2022 | 62 | 0.050 |
Why?
|
| Technology | 1 | 2022 | 52 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1121 | 0.050 |
Why?
|
| New England | 3 | 2010 | 273 | 0.050 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2020 | 4 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 22 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2023 | 483 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2020 | 36 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2020 | 143 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 137 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2015 | 1006 | 0.040 |
Why?
|
| Mammography | 1 | 2022 | 280 | 0.040 |
Why?
|
| Reward | 1 | 2020 | 87 | 0.040 |
Why?
|
| Goals | 1 | 2020 | 91 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2018 | 2076 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 319 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 4683 | 0.040 |
Why?
|
| Focus Groups | 1 | 2020 | 303 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 463 | 0.040 |
Why?
|
| Adolescent | 2 | 2020 | 6238 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 265 | 0.040 |
Why?
|
| Motivational Interviewing | 1 | 2018 | 43 | 0.040 |
Why?
|
| California | 1 | 2018 | 174 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 436 | 0.030 |
Why?
|
| Telephone | 1 | 2018 | 119 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 673 | 0.030 |
Why?
|
| Research Design | 1 | 2020 | 573 | 0.030 |
Why?
|
| Community Health Services | 1 | 2018 | 128 | 0.030 |
Why?
|
| Mass Screening | 1 | 2022 | 690 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 874 | 0.030 |
Why?
|
| Age Factors | 2 | 2014 | 1560 | 0.030 |
Why?
|
| Risk Factors | 2 | 2020 | 5343 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2014 | 240 | 0.030 |
Why?
|
| Propensity Score | 1 | 2014 | 156 | 0.030 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 13 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 163 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2014 | 76 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2014 | 103 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2013 | 21 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2013 | 37 | 0.030 |
Why?
|
| United States | 3 | 2014 | 7826 | 0.030 |
Why?
|
| Inappropriate Prescribing | 1 | 2013 | 66 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2013 | 2568 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 730 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2014 | 122 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 935 | 0.020 |
Why?
|
| Patient Safety | 1 | 2014 | 243 | 0.020 |
Why?
|
| Data Collection | 1 | 2013 | 384 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 777 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2014 | 509 | 0.020 |
Why?
|
| Prescription Drugs | 1 | 2011 | 51 | 0.020 |
Why?
|
| Length of Stay | 1 | 2014 | 811 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2012 | 116 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 417 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 863 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 834 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 2571 | 0.010 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2004 | 36 | 0.010 |
Why?
|
| Diuretics | 1 | 2004 | 62 | 0.010 |
Why?
|
| Medical Records | 1 | 2004 | 137 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2004 | 107 | 0.010 |
Why?
|
| Medicare Part B | 1 | 2003 | 11 | 0.010 |
Why?
|
| Medicare Part C | 1 | 2003 | 14 | 0.010 |
Why?
|
| Sex Factors | 1 | 2004 | 979 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2004 | 495 | 0.010 |
Why?
|
| Medicare | 1 | 2004 | 610 | 0.010 |
Why?
|